



The Treatment of Adults with Essential Hypertension

STEVEN A. DOSH, MD, MS
Escanaba, Michigan

Hypertension is arbitrarily defined as diastolic blood pressure (DBP) of 90 mm Hg or higher, systolic blood pressure (SBP) of 140 mm Hg or higher, or both, on 3 separate occasions. Essential hypertension is hypertension without an identifiable cause. Essential hypertension, also known as primary or idiopathic hypertension, accounts for at least 95% of all cases of hypertension.

According to the third National Health and Nutrition Examination Survey (NHANES III), approximately 60% of the 50 million Americans with hypertension are at increased risk for cardiovascular disease resulting from uncontrolled hypertension. This is because only 53% of hypertensive patients are being treated and only 24% have their hypertension under control.¹ Physicians must play an active role in identifying and treating hypertension.

In an earlier Applied Evidence article² an approach to the diagnosis of hypertension was presented. This article reviews the treatment of essential hypertension in adults and the prognosis of untreated hypertension. Risk stratification, alternative therapies, lifestyle modification, drug therapy, and prognosis will each be reviewed sequentially.

■ **KEY WORDS** Blood pressure; hypertension; prognosis; therapy; acupuncture; alternative therapy; biofeedback; herbal medicine; transcendental meditation; yoga. (*J Fam Pract* 2002; 51:74-79)

RISK STRATIFICATION

The decision to treat hypertension and the choice of treatment is affected by the patient's risk of morbidity and mortality if the blood pressure remains untreated or under-treated. According to the recommendations of the sixth report of the Joint National Committee on the Prevention, Diagnosis, Evaluation, and Treatment of High Blood Pressure (JNC-VI), the first step in planning treatment of a patient with essential hypertension is to categorize the patient's risk status.³ The patient is placed in 1 of 9 treatment categories according to his or her blood pressure

KEY POINTS FOR CLINICIANS

- Only 53% of hypertensive patients are being treated, and only 24% have their hypertension under control.
- The first step in planning the treatment of a patient with essential hypertension is to categorize the patient's risk status.
- The target blood pressure of patients who have diabetes or renal failure should be less than 130/85.
- Diuretics are safe, well tolerated, effective, relatively inexpensive, and convenient for initial drug treatment of hypertension in patients who do not have concomitant illness.
- Alpha-adrenergic blockers should be used with caution in the treatment of hypertension.
- Ambulatory blood pressure measurements predict cardiovascular events more closely than clinic blood pressure measurements.

category, cardiovascular risk factors, and evidence of end-organ damage found during the initial evaluation (Table 1). Once the treatment category is identified, initial treatment should begin (Figure 1). Subsequent treatment depends on the patient's response to initial treatment (Figure 2).

Patients should be monitored regularly to be sure they do not develop signs and symptoms that would place them in a different category and mandate more aggressive treatment. After a patient's blood pressure has been controlled for 1 year, it may be possible to decrease the dose or the number of antihypertensive drugs—especially among patients who make significant lifestyle changes.⁴

The effectiveness of therapy varies depending on the patient's cardiovascular risk. The New Zealand

•Submitted, revised, September 4, 2001.

From the OSF Medical Group. Reprint requests should be addressed to Steven A. Dosh, MD, MS, OSF Medical Group, 3409 Ludington, Escanaba, MI 49837. E-mail: doshstev@msu.edu.

Guidelines Group has developed a helpful risk calculator based on the Framingham Heart Study for estimating a patient's cardiovascular risk. This calculator incorporates sex, age, systolic blood pressure, smoking status, total cholesterol, high-density lipoprotein cholesterol, presence or absence of diabetes, and presence or absence of electrocardiogram evidence of left ventricular hypertrophy. This helpful risk calculator may be downloaded from the Web site of the New Zealand Guidelines Group at http://www.nzgg.org.nz/library/gl_complete/blood-pressure/appendix.cfm#app3. Alternatively, the University of Sheffield Medical School has developed tables to estimate an individual's risk of heart disease based on cardiovascular risk factors including age, sex, cholesterol level, and presence or absence of smoking, hypertension, and diabetes—Sheffield tables.⁵ Software for handheld computers (Palm and PocketPC) that helps you estimate risk is available at www.jfponline.com.

Regardless of the method used, the benefit of treatment increases steadily as the patient's current cardiovascular risk increases. With a 5-year cardiovascular risk of less than 2.5%, more than 120 patients have to be treated for 5 years to prevent 1 cardiovascular event; this number decreases to 25 patients with a risk of between 5% and 10%, and only 13 with a risk of between 20% and 24%.⁶ It is tempting to assume that the benefit of hypertension treatment is related to reduction in blood pressure whether achieved by drug therapy, lifestyle modification, or alternative therapy. However, this has not been established and it is important to consider the evidence supporting the benefit of each of these therapeutic options (Table 2).

TREATMENT

Drug Therapy

Patients who require drug treatment for hypertension should begin with a low dose of the initial medication, and that dose should be slowly titrated upward every 1 to 2 months (Figure 2). The JNC-VI recommends a diuretic or a β -blocker with once daily dosing and 24-hour efficacy as the initial treatment for most hypertensive patients. However, the choice of initial medication will be affected by concomitant illnesses: (1) β -blockers are recommended for the initial treatment of patients with hypertension and a history of coronary artery disease; (2) diuretics are suggested for the initial treatment of isolated systolic hypertension; (3) and angiotensin-converting enzyme (ACE) inhibitors are recommended for hypertensive patients who have systolic dysfunction after myocardial infarction, diabetic nephropathy, or congestive heart failure. Angiotensin II receptor blockers may be used in patients who cannot tolerate ACE inhibitors because of cough or rash. Alpha-adrenergic blockers should be used with caution in light of evidence that they may increase the risk of cardiovascular events (especially congestive heart failure).⁷

Among patients who do not have concomitant illness, the choice of drug therapy is controversial. A case-control study and a meta-analysis suggested that short-acting calcium channel blockers (CCBs) increase cardiovascular mortality.^{8,9} Unfortunately, these studies were not designed to establish a causal relationship. A recent nonsystematic review suggested that short-acting CCBs should be avoided and that conventional therapies were more effective than long-acting CCBs.¹⁰ An earlier non-systematic review

suggested that short- and intermediate-acting CCBs were associated with increased cardiovascular mortality and morbidity. However, a well-designed cohort study of patients with coronary artery disease failed to reveal an increase in adverse effects among patients taking short-acting CCBs.¹¹ Furthermore, randomized controlled trials suggest that diuretics, β -blockers, and long-acting CCBs are equally effective in preventing cardiovascular mortality and morbidity.^{12,13} Physicians who treat hypertension must choose the best initial treat-

TABLE 1
HYPERTENSION RISK STRATIFICATION AND TREATMENT CATEGORIES

Blood Pressure Category	Risk Group A*	Risk Group B*	Risk Group C*
High-normal (130 – 139/85 – 89)	Lifestyle modification†	Lifestyle modification	Lifestyle modification and drug therapy
Stage 1 (140 – 159/90 – 99)	Lifestyle modification (12-month trial)	Lifestyle modification (6-month trial)	Lifestyle modification and drug therapy
Stage 2 or 3 (≥ 160 / ≥ 100)	Lifestyle modification and drug therapy	Lifestyle modification and drug therapy	Lifestyle modification and drug therapy

*Risk groups: A = no risk factors, end-organ damage, or clinical cardiovascular disease; B = ≥ 1 risk factor other than diabetes, no end-organ damage, and no clinical cardiovascular disease; C = Diabetes, end-organ damage, or clinic cardiovascular disease.
† Lifestyle modification should be included in the treatment plan of all patients receiving drug therapy.

TABLE 2
NUMBER NEEDED TO TREAT (NNT) FOR SPECIFIC ANTIHYPERTENSIVE TREATMENTS

Medication	Level of Evidence	NNT (95% CI)*	Comment
Low-Dose Thiazide	1a	18 (14-23)	Adults with systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 90 regardless of age or comorbidities.
High-Dose Thiazide	1a	67 (48-111)	Drug vs no treatment comparison. ¹⁴
Beta-Blocker	1a	142 (71-1000)	
Calcium-Channel Blockers	1b	45 (30-102)	Isolated systolic hypertension in older patients, drug vs no treatment comparison. ²²
ACE inhibitors	1b	NS	Captopril versus diuretic or β -blocker.
Alpha-agonists	1b	NS	Doxazosin versus chlorthalidone, increased congestive heart in doxazosin group. ⁷
ARBs	NA	NA	Patient-oriented outcomes not available.
Sodium Restriction	1a	NA	May reduce blood pressure but lacks evidence of reduced morbidity or mortality. ²⁷⁻³⁵
Weight Loss	1a	NA	
Exercise	1a	NA	
Low-Fat Diet	1b	NA	
Limited Alcohol	5	NA	
Potassium Supplement	1a	NA	
Fish Oil Supplement	1a	NA	
Acupuncture	NA	NA	No evidence of blood pressure reduction or reduced morbidity or mortality. ³⁶⁻⁴³
Biofeedback	NA	NA	
Herbal Medicine	NA	NA	
Transcendental Meditation	NA	NA	
Yoga	NA	NA	
*For total cardiovascular events over 5 years. NS denotes no significant difference from comparison drug; NA, not applicable; ACE, angiotensin-converting enzyme; ARBs, angiotensin-receptor blockers.			

ment for patients who do not have concomitant illness. Fortunately, safety, tolerability, efficacy, price, and simplicity can guide the physician to an ideal drug for most hypertensive patients.

Low-dose thiazide diuretics (the equivalent of 25 to 50 mg of hydrochlorothiazide) appear better tolerated than β -blockers or CCBs.¹⁴ Treatment with β -blockers, CCBs, and ACE inhibitors is also more expensive (75% to 85% more) than diuretic therapy.¹⁵ The cost savings offered by diuretics complement the fact that diuretics are safe, effective, and may be dosed once daily. In short, in addition to being the drug of choice for isolated systolic hypertension, low-dose thiazide diuretics are the ideal initial drug treatment of patients without concomitant illness. It should be noted that higher doses of thiazide diuretics offer proportionately less blood pressure reduction and greater risk of hypokalemia.¹⁶

Antihypertensive treatment reduces morbidity and

mortality for all stages of hypertension, but people with the greatest baseline cardiovascular risk (eg, older patients and patients with higher levels of blood pressure) have the most to gain from treatment.^{17,18}

There is no conclusive evidence to suggest that lowering blood pressure to below 140/80 reduces morbidity or mortality in most patients. However, patients who have diabetes or renal failure benefit from more aggressive management of blood pressure.^{19,20} Therefore, the JNC-VI recommends a target blood pressure of less than 130/85 for these patients.


The JNC-VI recommendation to start with a low-dose diuretic is supported by the evidence across a spectrum of patient-oriented outcomes. The effectiveness of diuretics and β -blockers as first-line

agents has been confirmed by long-term clinical trials.^{14,21} However, low-dose thiazides appear effective against a broader range of outcomes than high-dose thiazides and β -blockers (Table 3). There is also evidence to suggest that CCBs and ACE inhibitors may be effective first-line agents, but fewer patients have been studied who take CCBs and ACE inhibitors than those who take diuretics and β -blockers.^{22,23}

Most patients with hypertension will respond to 1 (approximately 50%) or 2 (approximately 30%) antihypertensive medications.^{19,24,25} As noted earlier, failure to respond to treatment suggests an identifiable cause of hypertension. Among patients who do not have a secondary cause of hypertension, inadequate drug treatment (often failure to start a diuretic) and noncompliance are among the most common causes of resistant hypertension.²⁶

When patients who are receiving drug therapy fail to reach the target blood pressure goal or fail to

FIGURE 1



maintain the blood pressure goal, they should have the initial drug dose increased until the goal is reached (Figure 2). Those who fail initial drug therapy at full doses should have a second drug added and increased until the blood pressure goal is reached. Those who fail initial and second drug therapy at full doses should have a third drug added and increased until the pressure goal is reached. Patients who fail to reach the goal on maximal doses of 3 drugs have, by definition, resistant hypertension and

will require evaluation by a physician with expertise in managing resistant hypertension. A cause should be sought each time a patient fails to respond to a drug or fails to maintain blood pressure control on a drug that had previously controlled the pressure (Table 3).

LIFESTYLE MODIFICATIONS

Several lifestyle modifications are recommended in all treatment categories. Aerobic exercise (45 to 60 minutes at least 3 days per week), low-salt, low-fat, and high fruit and vegetable diet, limited alcohol consumption (less than 3 drinks per day), and modest weight loss (3% to 9% of total body weight) have been demonstrated to yield modest blood pressure reductions, but there is insufficient evidence to suggest that these measures alone reduce morbidity or mortality in hypertensive patients.²⁷⁻³³ A systematic review of randomized controlled trials found an average 4.4/2.5 mm Hg reduction in blood pressure with no evidence of harm (among patients who were not at risk for hyperkalemia) when diet was supplemented with about 2000 mg of potassium daily.³⁴ A comparable reduction in blood pressure was seen with a daily supplement of more than 3 grams of fish oil.³⁵ Research concerning the value of calcium and magnesium supplementation is conflicting and insufficient for supplementation to be considered standard therapy at this time.

ALTERNATIVE THERAPY

The number and the quality of studies evaluating acupuncture, biofeedback, herbal medicine, transcendental meditation, and yoga are, for the most part, limited. They have focused on reduction in blood pressure, not patient-oriented outcomes, such as a reduction in morbidity and mortality. Acupuncture does not appear to have a significant effect on blood pressure levels.^{36,37} Biofeedback and

other behavioral techniques have not been demonstrated to reduce blood pressure.^{38,39} The effect of garlic on blood pressure is unclear with mixed study results.^{40,41} Transcendental meditation and yoga may reduce blood pressure, but studies of these modalities are small and the experimental designs have a limited capacity to detect an independent treatment effect or a placebo effect.^{42,43}

Therefore, physicians who include any of these modalities in their hypertension treatment plan should carefully monitor each patient for adequacy of blood pressure control, development of risk factors, and evidence of end-organ damage. At this time, alternative therapies should be considered experimental adjuncts to lifestyle modification and medical therapy that have not been shown to improve patient-oriented outcomes.

FOLLOW-UP OF PATIENTS WITH HYPERTENSION

Follow-up visits should be designed to identify new risk factors, evidence of end-organ damage, and adequacy of blood pressure control. Follow-up visits may include an interval history, limited physical examination, radiologic evaluation, and laboratory testing. The frequency and nature of follow-up hypertension evaluations will vary according to the presence or absence of preexisting risk factors, evidence of end-organ damage, the nature of the treatment the patient is receiving, and the stability of blood pressure control. Unfortunately, there is little evidence to support specific recommendations for the frequency and nature of follow-up hypertension evaluations.

In the absence of evidence, several general principles may be suggested. Patients should be seen within 2 months of initiation of treatment. Follow-up history should focus on the cardiovascular and neurologic review of systems. The examination should include a focused cardiovascular work-up (eg, retinopathy, carotid bruits). Consideration should be given to periodic laboratory testing for diabetes, renal insufficiency, and hyperlipidemia.

Periodic (but less frequent) chest x-rays and electrocardiograms may be helpful to detect cardiomegaly, but there is no evidence to support such testing in the absence of symptoms.

Follow-up visits should be more frequent among patients who have marginal blood pressure control, preexisting risk factors, or end-organ damage. Evaluations may be less frequent among those with

FIGURE 2




TABLE 3

PARTIAL LISTING OF CAUSES OF FAILURE TO REACH OR MAINTAIN TARGET BLOOD PRESSURE

Volume overload: failure to start a diuretic
 Nonadherence to therapy: dementia, side effects, complex regimen
 Drug-induced: prescription, over-the-counter, herbal, or illicit drugs
 Diet/stimulant induced: caffeine, licorice, salt, alcohol, nicotine
 Associated conditions: obesity, sleep apnea, anxiety, chronic pain
 Identifiable causes: chronic renal disease, renovascular disease, hyperaldosteronism, Cushing's syndrome, pheochromocytoma
 Pseudoresistance: wrong cuff size, white-coat hypertension

good control and no preexisting risk factors or end-organ damage. Office visits and testing should be more frequent whenever changes are made in treatment. The frequency and nature of follow-up testing will also depend on the nature of treatment. Patients taking diuretics should have their potassium levels checked periodically. Renal function and potassium should be monitored in patients who are taking ACE inhibitors, especially during the first few weeks of therapy.

Patients willing to regularly monitor their blood pressure at home may require less frequent follow-up than those who leave it to the physician to check. Patients who monitor their blood pressure at home should have their sphygmomanometers validated initially and periodically.⁴⁴ It is important to remember that home blood pressure measurements are consistently lower and more closely correlated with cardiovascular outcomes than are clinic blood pressure measurements.⁴⁵⁻⁴⁷

PROGNOSIS

It is difficult to estimate the precise impact blood pressure control has on morbidity and mortality, but it is clear that high blood pressure, if unrecognized or untreated, substantially increases the morbidity and mortality associated with coronary disease, heart failure, renal failure, and stroke.¹⁷ In an early study of untreated hypertension there was a close relationship between blood pressure level and cardiovascular morbidity over 14 years of observation. This study revealed that hypertensive patients (those with a blood pressure of $\geq 160/95$) had cardiovascular morbidity rates (coronary artery disease, claudication, stroke, and congestive heart failure) 2 to 3 times higher than normotensive patients.⁴⁸ The impact of inadequately controlled blood pressure on morbidity and mortality among patients with diabetes is especially problematic.⁴⁹ Over 9 years, when compared with diabetic patients with less tight control ($< 180/105$ mm Hg), those with tight blood pressure control ($< 150/85$ mm Hg) had a 24% reduction in sudden

death, hyperglycemic or hypoglycemic death, fatal or nonfatal myocardial infarction, angina, heart failure, fatal or nonfatal stroke, renal failure, amputation, vitreous hemorrhage, and retinal hemorrhage.

Finally, renal function deteriorates more rapidly when blood pressure control is inadequate in patients with chronic renal disease of diverse causes.²⁰ Over 2 years, when compared with patients with renal failure who had less tight control (mean arterial pressure ≤ 107 mm Hg), renal failure patients with tight control (mean arterial blood pressure ≤ 92 mm Hg) had significantly less proteinuria and lower rates of decline in renal function. Whether this translates into a significant improvement in the risk of end-stage renal disease is unknown.

REFERENCES

1. Burt V, Whelton P, Rocella E, Brown C, Cutler J. Prevalence of hypertension in the US population: results from the third national health and nutrition examination survey, 1988-1991. *Hypertension* 1995; 25:305-13.
2. Dosh S. The diagnosis of essential and secondary hypertension in adults. *J Fam Pract* 2001; 50:707-12.
3. Joint National Committee on the Prevention Detection, Evaluation, and Treatment of High Blood Pressure. the sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI). *Arch Intern Med* 1997; 157:2413-46.
4. Whelton P, Appelgate W, Ettinger W, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of non-pharmacologic interventions in the elderly (TONE). *JAMA* 1996; 279:839-46.
5. Wallis E, Ramsay L, Haq I, Ghahramani P, Jackson P. Coronary and cardiovascular risk estimation for the primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey. *Br Med J* 2000; 320:671-76.
6. Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. *Br Med J* 2000; 320:680-85.
7. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. *J Am Med Assoc* 2000; 283:1967-75.
8. Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with anti-hypertensive drug therapies. *JAMA* 1995; 274:620-25.
9. Furberg C, Psaty B, Meyer J. Nifedipine: dose related increase in mortality in patients with coronary heart disease. *Circulation* 1995; 92:1326-31.
10. Kizer J, Kimmel S. Epidemiologic review of the calcium channel blocker drugs. *Arch Intern Med* 2001; 161:1145-58.
11. Braun S, Boyo V, Behar S, et al. Calcium antagonists did not increase mortality in patients with coronary artery disease. *J Am Coll Cardiol* 1996; 28:7-11.
12. Hansson L, Hedner T, Lund-Johansen P, et al. Randomized trial of effects of calcium antagonists compared with diuretics and B-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet* 2000; 356:359-65.
13. Hansson L, Lindholm L, Ekbohm T, Dahlöf B. Randomised

- trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish trial in old patients with hypertension-2 study. *Lancet* 1999; 354:1751-56.
14. Wright J, Lee C, Chambers G. Systematic review of anti-hypertensive therapies: does evidence assist in choosing a first-line drug? *Can Med Assoc J* 1999; 161:25-32.
 15. Ramsey S, Niel N, Sullivan S, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. *J Am Board Fam Pract* 1999; 12:105-14.
 16. Wright J. Choosing a first-line drug in the management of elevated blood pressure: What is the evidence?: 1 Thiazide diuretics. *Can Med Assoc J* 2000; 163:57-60.
 17. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. *J Hum Hypertens* 1996; 10:1-8.
 18. Mulrow C, Cornell J, Herrera C, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly: implications and generalizability of randomized trials. *JAMA* 1994; 272:1932-38.
 19. Hansson L, Zanchetti A, Carruthers S, Dahlof B. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. *Lancet* 1998; 351:1755-62.
 20. Peterson J, Adler S, Burkart J, Greene J. Blood pressure control, proteinuria, and the progression of renal disease. *Ann Intern Med* 1995; 123:754-62.
 21. Psaty B, Smith N, Siscovick D, Koepsell T, Weiss N. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis. *J Am Med Assoc* 1997; 277:739-45.
 22. Staessen J, Fagard R, Celis H, Arabidze C, Birkenhager W. Randomised double-blind comparison of placebo and active treatment in older patients with isolated systolic hypertension. *Lancet* 1997; 350:757-64.
 23. Investigators THOPES. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *New Eng J Med* 2000; 342:145-53.
 24. Masterson B, Reda D, Preston R, et al. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. *Arch Intern Med* 1995; 155:1757-62.
 25. Tuomilehto J, Rastenyte D, Birkenhager W, et al. Systolic hypertension in Europe trial investigators. Effects of calcium-channel blockers in older patients with diabetes and systolic hypertension. *New Eng J Med* 1999; 340:677-84.
 26. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. *Arch Intern Med* 1991; 151:1786-92.
 27. Halbert J, Silagy C, Finucane P, Withers R. The effectiveness of exercise training in lowering blood pressure: a meta-analysis of randomized controlled trials of 4 weeks or longer. *J Human Hypertension* 1997; 10:641-49.
 28. Ebrahim S, Davey G. Lowering blood pressure: a systematic review of sustained effects of non-pharmacologic interventions. *J Public Health Med* 1998; 4:441-48.
 29. Appel L, Moore T, Obarzanek E, Vollmer W. A clinical trial of the effects of dietary patterns on blood pressure. *New Eng J Med* 1997; 336:1117-24.
 30. Appel L, Espeland M, Easter L, Wilson A, Folmar S, Lacy C. Effects of reduced sodium intake on hypertension control in older individuals. Results from the trial of nonpharmacologic interventions in the elderly (TONE). *Arch Intern Med* 2001; 161:685-93.
 31. Beilin L, Puddey I, Burke V. Alcohol and hypertension: kill or cure? *J Human Hypertension* 1996; 10(Suppl 2):1-5.
 32. Corrigan S, Raczynski J, Swencionis C, Jennings S. Weight reduction in the prevention and treatment of hypertension: a review of representative clinical trials. *Am J Health Promo* 1991; 5:208-14.
 33. Mulrow C, Chiquette E, Angel L, Cornell J. Dieting to reduce body weight for controlling hypertension in adults. *The Cochrane Library* 2001.
 34. Whelton P, He J, Cutler J, Brancati F, Appel L. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled trials. *JAMA* 1997; 277:1624-32.
 35. Morris M, Sacks F, Rosner B. Regulation on blood pressure: does fish oil lower blood pressure?: analysis of controlled trials. *Circulation* 1993; 88:523-33.
 36. Sugioka K, Woods M, Mueller R. An unsuccessful attempt to treat hypertension with acupuncture. *Am J Chinese Med* 1977; 5:39-44.
 37. Kraft K, Coulon S. Effect of a standardized acupuncture treatment on complaints, blood pressure, and serum lipids of hypertensive, postmenopausal women. A randomized controlled clinical study. *Forschende Komplementarmedizin* 1999; 6:74-79.
 38. Eisenberg D, Delblanco T, Berkey C, et al. Cognitive and behavioral techniques and hypertension: a meta-analysis. *Ann Intern Med* 1993; 118:964-72.
 39. Hunyor S, Henderson R, Saroj K, Carter N, et al. Placebo-controlled biofeedback blood pressure effect in hypertensive humans. *Hypertension* 1997; 29:1225-31.
 40. Auer W. Hypertension and hyperlipidemia: garlic helps in mild cases. *Br J Clin Pract* 1990; 69(Suppl):3-6.
 41. Ackerman R, Mulrow C, Ramirez G, Gardner C, Mobidoni L, Lawrence V. Garlic shows promise for improving some cardiovascular risk factors. *Arch Intern Med* 2001; 161:813-24.
 42. Patel C. Twelve-month follow-up of yoga and bio-feedback in the management of hypertension. *Lancet* 1975; 1:62-64.
 43. Sundar S, Agrawal S, Singh V, Bhattacharya S, et al. Role of yoga in management of essential hypertension. *Acta Cardiologica* 1984; 39:203-08.
 44. White W, Berson A, Robbins C, Jamieson M, Prisant L. National standard for measurement of resting and ambulatory blood pressure with automated sphygmomanometers. *Hypertension* 1993; 21:504-09.
 45. Staessen J, Byttebier G, Butinx F, Celis H, O'Brien E. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. *J Am Med Assoc* 1997; 278:1065-72.
 46. Ohkubo T, Imai Y, Tsuji I, Nagai K, Ito S. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasma study. *Hypertension* 1998; 32:255-59.
 47. Staessen J, Thijs L, Fagard R, O'Brien E, Eoin T. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. *JAMA* 1999; 282:539-46.
 48. Kannel W, Wolf P, Verter J, McNamara P. Epidemiologic assessment of the role of blood pressure in stroke: the Framingham study. *JAMA* 1970; 214:301-10.
 49. Turner R, Holman R, Stratton I, Cull C. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *Br Med J* 1998; 317:703-12.